Levamisole: A multi-faceted drug in dermatology

Mrinal Gupta

INTRODUCTION

Levamisole is a synthetic antihelminthic belonging to the class of imidazothiazole derivatives, possessing potent immunomodulatory activity. It has been extensively used in dermatology practice for the management of various dermatoses ranging from infections such as warts and leprosy to inflammatory dermatoses such as lichen planus and Behcet's disease [Table 1].[1,2]

PHARMACOLOGY

Levamisole, the levo-isomer of tetramisole, is readily soluble in water and is rapidly absorbed from the gastrointestinal tract; peak blood levels are achieved after 1.5–4 h. Its plasma half-life is 16 h and it is metabolized mainly in the liver.[1,3] Usually, it is administered at a dose of 150 mg/day for 2–4 days each week but for the management of malignancies or immunodeficiencies a higher dose or prolonged treatment regimens are recommended.[1,4]

MECHANISM OF ACTION

Levamisole exerts its antihelminthic activity by acting as a nicotinic acetylcholine receptor agonist.[3] It possesses a wide range of immunomodulatory properties and mainly acts on macrophages and T-lymphocytes augmenting their functions such as phagocytosis, chemotaxis, adherence, intracellular killing, E-rosette formation, delayed skin hypersensitivity and antigen-induced proliferation. Levamisole seems to have a preferential effect on T helper-1 cells with subsequent upregulation of interleukin-2, interleukin-12 and interferon-γ. It has also been demonstrated to inhibit the action of endogenous immunosuppressive factors like soluble immune response suppressor. Elevated B-cell activity is also inhibited by levamisole as indicated by reduced immunoglobulin G, immunoglobulin M and circulating immune complex levels.[5-7] The drug possesses anti-anergic properties restoring depressed immune responses with only marginal effects in immunologically competent individuals.

LEVAMISOLE IN DERMATOLOGY

The various therapeutic uses of levamisole in dermatology practice are reviewed below.

INFECTIONS AND INFESTATIONS

Warts

Warts are a common dermatological problem caused by the human papillomavirus, with numerous treatment modalities available. Levamisole has been used in combination with cimetidine for the management of recalcitrant warts. In a double-blind comparative trial, the efficacy of a combination of cimetidine and levamisole was compared with cimetidine alone in 48 patients with multiple recalcitrant warts.[8] The patients were divided into two groups, one receiving oral cimetidine alone in a dose of 30 mg/kg/day orally in three divided doses up to a maximum of 3 g/day and the other receiving levamisole 150 mg tablets on 2 consecutive days a week, in addition to cimetidine. After 12 weeks of therapy, 75% of patients in the combination therapy group showed marked to complete response, compared to 41.6% of patients in

Sudhaa Skin Centre, Treatwell Clinic, Canal Road, Jammu, Jammu and Kashmir, India

Address for correspondence: Dr. Mrinal Gupta, Sudhaa Skin Centre, Treatwell Clinic, Canal Road, Jammu - 180 001, Jammu and Kashmir, India. E-mail: drmrinalgupta@yahoo.com

How to cite this article: Gupta M. Levamisole: A multi-faceted drug in dermatology. Indian J Dermatol Venereol Leprol 2016;82:230-6.

Received: March, 2015. Accepted: November, 2015.
the cimetidine-only group. The average regression periods were 7 and 10 weeks respectively. In another similar study on 44 children with multiple recalcitrant warts, complete response was observed in 65% of patients on levamisole plus cimetidine and in only 31.5% of those on cimetidine alone after 12 weeks of therapy. However, some randomized controlled trials failed to find any statistically significant improvement with levamisole in the treatment of multiple viral warts.

Cutaneous leishmaniasis

Cutaneous leishmaniasis, caused by parasites of *Leishmania* spp., causes significant morbidity due to its long clinical course and residual scarring. Levamisole has been reported to be effective and safe in its management. Complete clearance of lesions of chronic cutaneous leishmaniasis was reported in 28 patients within 2 months of starting levamisole, 150 mg twice weekly without any significant adverse effects. Similar results have been reported by other researchers. Although these results are encouraging, further studies are needed before making any recommendations.

Herpesvirus infections

Levamisole has been found useful in the management of herpes labialis and herpes genitalis. In a randomized controlled trial, 33 patients with recurrent herpes labialis or herpes genitalis were randomly allocated to receive levamisole (2.5 mg/kg) or placebo on 2 consecutive days each week for 26 weeks. Seven (33%) of 21 patients with recurrent herpes genitalis showed complete response and 10 (47%) showed a partial response to levamisole. Six (50%) of 12 patients with herpes labialis showed complete or partial responses. Levamisole was found to produce significantly greater reductions in frequency, duration and severity of herpes attacks than placebo. Another double-blind controlled trial including 48 patients with recurrent herpes labialis showed a reduction in the number of recurrences with levamisole 2.5 mg/kg on 2 consecutive days each week for 6 months. Researchers have also found that lesions of herpes zoster healed faster when levamisole was given as an adjuvant with acyclovir than with acyclovir alone.

Superficial fungal infections

A double-blind, placebo-controlled, randomized trial on 26 patients of chronic dermatophytosis due to *Trichophyton rubrum* showed a significantly stronger immunological response with griseofulvin plus levamisole than with griseofulvin plus placebo, although the clinical cure rates in both groups were similar. Levamisole was also found to hasten the remission of oral candidiasis when given as an adjuvant with nystatin in patients with impaired cell-mediated immunity.

Leprosy

Levamisole has been found useful in inducing rapid bacterial clearance in leprosy and in the management of lepra reactions owing to its immunostimulatory properties. When given as an adjuvant with multidrug therapy, it induced significantly higher bacteriological improvement than multidrug therapy alone. In a placebo-controlled trial on 20 patients of subpolar lepromatous leprosy, levamisole added as an adjuvant to chemotherapy for 1 year was found to induce a statistically significantly greater bacteriological improvement than chemotherapy alone. Levamisole has also been tried in mild to moderate erythema nodosum leprosum. In a dose of 150 mg daily for 3 consecutive days every 12 days, it brought down reactions faster than clofazimine. However, a Cochrane review of the different treatment modalities...
in erythema nodosum leprosum reported no significant difference between levamisole and placebo after 3 months of therapy.[23]

**Pediculosis**
A uncontrolled, open, pilot study included 28 patients of pediculosis capitis treated with oral levamisole (3.5 mg/kg/day) for 10 days.[24] On the 11th day, meticulous hair examination revealed that 23 (85%) patients had responded to treatment with 18 (67%) having responded completely and 5 (19%), partially.

**Pyoderma**
Significant clinical improvement in chronic pyoderma has been reported with levamisole and this has been attributed to its T-cell stimulatory action. There are numerous reports of clearance of resistant bacterial infections with levamisole in patients with impaired cellular immunity.[25,26]

**Human immunodeficiency virus**
Owing to its immunomodulatory and antiviral activity, levamisole has been used in the management of HIV-positive patients either as monotherapy or as an adjuvant with antiretroviral treatment. Its use has been recommended before the patient’s transition to full-blown AIDS. In one study, 50 HIV-affected children who were not on antiretroviral therapy received only levamisole in a dose of 2 mg/kg/day for 3 days each week for 24–52 weeks. The number of infections (275 vs. 455), progression to AIDS (14% vs. 60%) and number of deaths (4 vs. 28) were significantly less than in the control group over a follow-up period of 18 months.[27] However, in another study, among 178 HIV-positive patients with CD4 counts <350 and not receiving antiretroviral drugs, supplementation with selenium and levamisole 50 mg thrice weekly every alternate day led to significant increases in CD4 cell counts after 6 months of therapy while CD4 counts decreased significantly in the group receiving levamisole alone.[28]

**INFLAMMATORY DERMATOSES**

**Erythema multiforme**
In an open-prospective study, 39 patients of erythema multiforme were treated with either levamisole 150 mg thrice weekly alone, or in combination with systemic corticosteroids for as long as there was evidence of disease.[29] Thirty-one patients showed a complete response while four responded partially to levamisole therapy. Others have also reported similar results which have been attributed to its effect on the inflammatory responses including sequestration or elimination of persistent antigen and increasing interleukin-2 production by T lymphocytes.[30,31]

**Lichen planus**
Levamisole reduces the levels of tumor necrosis factor-α, interleukin-6 and interleukin-8 in patients with oral lichen planus and it has been found to be effective in oral lichen planus either alone or as an adjuvant to systemic corticosteroids.[32-35] Twenty three patients with oral lichen planus were treated with levamisole 150 mg thrice weekly and low-dose oral corticosteroids in a prospective trial.[34] After 4 weeks of treatment, all the patients had over 80% improvement and the duration of remission was 9.5 months. Another report described 11 patients with oral lichen planus who were unable to take oral steroids and were treated with levamisole 50 mg thrice weekly.[35] Significant clinical improvement was seen at 2, 4 and 12 weeks of therapy with 5 patients showing complete clearance and 3 showing partial clearance at the end of 12 weeks. Clinical improvement was evident by 2 weeks while the mean duration to achieve clearance of skin lesions was 6.2 weeks.

**Behcet’s disease**
Levamisole has been used as a treatment modality for recurrent oral aphthae and Behcet’s disease.[36-38] One report describes 30 patients of Behcet’s disease who were treated with levamisole (150 mg every day in seven patients and 150 mg daily for 3 consecutive days every week in the others for an unspecified duration).[36] Five discontinued the therapy owing to adverse effects. Muco-cutaneous manifestations improved in two-thirds of the treated patients and uveitis in half. Improvement was also noted in arthritis. However, in another trial, levamisole was found ineffective in the prophylactic treatment of recurrent aphthous stomatitis.[39]

**Acne vulgaris**
Levamisole has been found to be an effective adjuvant with oral antibiotics in acne management. In a double-blind trial, 60 patients of acne vulgaris were randomized into two groups, one receiving doxycycline 100 mg/day with levamisole 2.5 mg/kg/week (up to 150 mg/week) and the other group receiving only daily doxycycline.[40] After 6 months, significant reductions were seen in total lesion counts, the acne severity index and papule/pustule and nodule/cyst counts in the levamisole group. Another similar study compared
azithromycin alone and azithromycin with levamisole in 169 patients of acne vulgaris. In 2 months, statistically significant improvements were seen with levamisole with reduced numbers of papules/pustules and nodules/cysts. There have also been numerous reports of the efficacy of levamisole in acne fulminans and acne conglobata.

**Vitiligo**
Levamisole, alone or as an adjuvant, has been found useful in controlling disease progression in vitiligo. A randomized, placebo-controlled, double-blind Indian study assessed the efficacy of levamisole in slowly spreading, limited vitiligo. Sixty patients with vitiligo involving <2% of the body surface area were randomly allocated to receive oral levamisole 150 mg or placebo on 2 consecutive days in a week along with daily topical 0.1% mometasone cream. At the end of 6 months, the proportion of patients who did not develop any new lesions was higher in the levamisole group though the difference between the two groups was not statistically significant. Another Indian study found that 94% of patients with active disease had arrest of disease activity within 2–4 months with repigmentation in 64% when treated with levamisole alone, in 87% of those treated with levamisole plus topical fluocinolone acetonide, and all patients treated with levamisole and topical clobetasol. Other researchers have also reported significant improvements in vitiligo, both in terms of repigmentation and cessation of disease progression with adjuvant levamisole therapy. In view of these studies, levamisole can be considered a safe and inexpensive adjuvant for the management of vitiligo.

**Collagen vascular diseases**
Levamisole has been tried in connective tissue disorders, where it may act via restoration of delayed hypersensitivity responses and improvement of impaired T-cell function and defective macrophage activity. One report described 8 patients with systemic lupus erythematosus treated with levamisole of whom 4 showed improvements in their skin lesions as well as in the levels of C1q and C3 over a period of 12 months. Another report described 20 patients of systemic lupus erythematosus treated with levamisole (150 mg/week for 3 to 24 months) with 16 of them showing improvements in clinical symptoms, reduction of proteinuria, increase in creatinine clearance and diminished levels of antinuclear antibodies. A statistically significant rise in the levels of C3 and C4 was observed at 4 months and maintained at 6–12 months in this study.

**Miscellaneous**
There are numerous reports on the use of levamisole in other cutaneous disorders such as psoriasis, pemphigus vulgaris, bullous pemphigoid, lichen nitidus, lichenoid dermatitis, alopecia areata, sarcoidosis and malignant melanoma but there are no controlled studies or appropriately blinded randomized trials to advocate the use of levamisole in these conditions.

**ADVERSE EFFECTS**
Levamisole is a U.S. Food and Drug Administration pregnancy category C drug and is considered safe during lactation. The adverse effects of levamisole are generally mild and transient and rarely warrant its discontinuation. Common adverse effects include abdominal symptoms such as nausea and abdominal cramps, a flu-like syndrome and arthralgias. There are however reports of agranulocytosis, multifocal leukoencephalopathy, ataxia, psychosis, myopathy, lichenoid eruptions, leg ulcers, fixed drug eruptions, necrotizing vasculitis and retiform purpura. Levamisole has been used as an adulterant of cocaine as it enhances the euphoric effects of the drug; this has led to a large number of cases of agranulocytosis in addicts using adulterated cocaine.

**CONCLUSION**
Levamisole is an immunomodulator which can be used in a large number of dermatological disorders. However, it cannot replace first-line therapeutic modalities as most of the studies of its efficacy have a small sample size. More evidence from blinded randomized control trials and case–control studies in various dermatoses is needed to determine its efficacy and to compare it with established treatments. Nevertheless, this low-cost drug can be used as an adjuvant to established modalities.

**Financial support and sponsorship**
Nil.
| Indication                      | Nature of study                  | Dosage                                                                 | Comments                                                                 | References |
|--------------------------------|----------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|------------|
| Warts                          | Double-blind randomized control trial | Cimeditine 30 mg/kg/day alone versus levamisole 150 mg for 2 consecutive days per week with cimeditine for 12 weeks | Levamisole in combination with cimeditine induced a rapid and more effective clearance of warts | [8]        |
|                                | Double-blind randomized control trial | Cimeditine 30 mg/kg/day alone versus levamisole 2.5 mg/kg for 2 consecutive days per week with cimeditine for 12 weeks | Levamisole in combination with cimeditine more effective in treating recalcitrant warts | [9]        |
|                                | Double-blind, placebo-controlled randomized trial | Levamisole 5 mg/kg/day for 3 consecutive days every 2 weeks for up to 5 months versus placebo | Higher cure rates seen with levamisole therapy in plane and common warts | [63]       |
| Cutaneous leishmaniasis        | Case report                      | Dosage of 50 mg 3 times daily on 2 successive days each week to a maximum dose of 2400 mg in 8 weeks | Levamisole induced clearance of lesions of cutaneous leishmaniasis without any adverse effects | [13]       |
| Herpes zoster                  | Double-blind placebo-controlled randomized trial | Levamisole 150 mg/day for 2 consecutive days every week | Levamisole led to faster skin clearance and fewer days of hospitalization than placebo group | [16]       |
| Herpes simplex                 | Double-blind placebo-controlled trial | Levamisole 150 mg/day for 2 consecutive days every week | No significant difference in duration or severity of disease was observed with levamisole | [16]       |
|                                | Open-label trial                 | MDT alone versus MDT along with levamisole 150 mg twice weekly for 1 year in patients of lepromatous leprosy | Addition of levamisole led to significant bacteriological improvement than with MDT alone | [20]       |
| Leprosy and lepra reactions    | Open-label trial                 | MDT alone versus MDT along with levamisole 150 mg twice weekly for 1 year in patients of borderline lepromatous and lepromatous leprosy | Rapid bacteriological clearance seen with adjuvant levamisole therapy than with MDT alone | [1]        |
|                                | Open-label trial                 | Levamisole 150 mg/day for 3 days repeated every 12 days with dapsone, compared with dapsone and clofazimine and dapsone alone for 6 months | Levamisole was useful in bringing down both the types of reactions in a period shorter than required by clofazimine | [22]       |
| Lichen planus                  | Open-label trial                 | Levamisole 150 mg/day for 3 consecutive days with 15 mg/day prednisolone in patients with refractory oral lichen planus | Significant clinical improvement seen with levamisole within 4-6 weeks of therapy | [34]       |
|                                | Open-label trial                 | Levamisole monotherapy 150 mg/day for 3 consecutive days per week in patients with oral lichen planus | Significant clinical improvement seen with levamisole monotherapy without any adverse effects | [35]       |
| Aphthous stomatitis           | Single-blind placebo-controlled trial | Levamisole alone (50 mg/day for 3 days) versus placebo versus levamisole and prednisolone 5 mg/day in patients with recurrent aphthous stomatitis | Statistically significant improvement noted in pain due to ulcers, number of ulcers/episode, size of ulcers, duration of ulcers and frequency of ulcers with levamisole therapy | [65]       |
| Vitiligo                       | Randomized double-blind trial    | Levamisole 150 mg/day for 2 consecutive days in adults and 100 mg/day for 2 consecutive days in children with 0.1% mometasone furoate cream daily in patients with limited and slowly spreading vitiligo for 6 months | The proportion of patients who did not develop any new lesions was higher in the levamisole group, but the difference between the two groups was not statistically significant | [44]       |
|                                | Open-label trial                 | Levamisole 150 mg/day for 2 consecutive days every week alone and with topical fluocinolone 0.1% and clobetasol propionate 0.05% cream was used in patients with limited and slowly spreading vitiligo | Levamisole led to significant arrest of disease activity and spontaneous repigmentation without any significant adverse effects | [45]       |
| Acne vulgaris                  | Open-label trial                 | Levamisole 150 mg/day (50 mg/day for children) for 2 consecutive days every week with 0.1% hydrocortisone butyrate cream twice daily in eyelid vitiligo | Levamisole-induced significant repigmentation within 6-8 weeks of therapy | [67]       |

Contd...
**Table 2: Contd...**

| Indication | Nature of study                  | Dosage                                                                 | Comments                                                                 | References |
|------------|----------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------------|------------|
| Double-blind, randomized, placebo-controlled trial | Doxycycline 100 mg/day alone was compared with doxycycline and levamisol 2.5 mg/kg/week (up to 150 mg/week) in patients suffering from severe nodulocystic acne | Levamisole induced a reduction in total lesions count, acne severity index and papule/pustule and nodula/cyst count than with doxycycline alone | [40]       |
| Single blind randomized control trial             | Azithromycin alone versus levamisole and azithromycin in patients with inflammatory acne | Addition of levamisole led to significant reduction of inflammatory lesions, more than with azithromycin alone | [41]       |

**MDT:** Multidrug therapy

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Scheinfeld N, Rosenberg JD, Weinberg JM. Levamisole in dermatology: A review. Am J Clin Dermatol 2004;5:97-104.
2. Allen DE, Kaplan B, Pinnell SR. Levamisole and skin disease. Int J Dermatol 1978;17:287-300.
3. Renaux G. The general immunopharmacology of levamisole. Drugs 1980;20:89-99.
4. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
5. Renaux G. Modulation of immunity by levamisole. J Pharmacol Ther 1978;2:288-96.
6. Van Wauwe J, Janssen PA. On the biochemical mode of action of levamisole: An update. Int J Immunopharmacol 1991;13:3-9.
7. Hadden JW. T-cell adjuvants. Int J Immunopharmacol 1994;16:703-10.
8. Parsad D, Saini R, Negi KS. Comparison of combination of cimetidine and levamisole with cimetidine alone in the treatment of recalcitrant warts. Australas J Dermatol 1999;40:93-5.
9. Parsad D, Pandhi R, Joneja A, Negi KS. Cimetidine and levamisole versus cimetidine alone for recalcitrant warts in children. Pediatr Dermatol 2001;18:349-52.
10. Schou M, Helin P. Levamisole in a double-blind study: No effect on warts. Acta Derm Venereol 1977;57:449-54.
11. Saúl A, Sanz R, Gomez M. Treatment of multiple viral warts with levamisole. Int J Dermatol 1980;19:342-3.
12. Butler PG. Levamisole therapy of chronic Leishmania tropica. J Trop Med Hyg 1978;81:221-4.
13. Butler PG. Levamisole and immune response phenomena in cutaneous leishmaniasis. J Am Acad Dermatol 1982;6:1070-7.
14. Makled M, Rifat M, Azab M, Makhlouf S, El-Missery A, Khalil N. Determination of healing response by immunostimulant therapy (levamisole) in cutaneous leishmaniasis. Chemioterapia 1987;6:2 Suppl: 214-6.
15. Jose DG, Minty CC. Levamisole in patients with recurrent herpes infection. Med J Aust 1980;2:390-4.
16. Russell AS, Brisson E, Grace M. A double-blind, controlled trial of levamisole in the treatment of recurrent herpes labialis. J Infect Dis 1978;137:597-600.
17. Smirnov IU, Shishov AS, Bagrov FI, Rudometov IU, Sverdlova LL. Levamisole in the treatment of different forms of herpes zoster. Zh Nevropatol Psikhiatr Im S S Korsakova 1983;83:511-5.
18. Sveigaard E, Christiansen AH, Stahl D, Thomesen K. Clinical and immunological studies in chronic dermatothyphosis caused by Trichophyton rubrum. Acta Derm Venereol 1984;64:493-500.
19. Lai WH, Lu SY, Eng HL. Levamisole aids in treatment of refractory oral candidiasis in two patients with thymoma associated with myasthenia gravis: Report of two cases. Chang Gung Med J 2002;25:606-11.
20. Kar HK, Bhatia VN, Kumar CH, Sirumban P, Roy PG. Evaluation of levamisole, an immunopotentiator, in the treatment of lepromatous leprosy. Indian J Lepr 1986;58:592-600.
21. Bera DK, Sen PC. Effect of levamisole on bacterial index in BL and LL leprosy. Int J Lepr Other Mycobact Dis 1985;53:198-200.
22. Sharma L, Thalliaith GH, Gargia HS, Sen PC. A comparative evaluation of levamisole in leprosy. Indian J Lepr 1985;57:11-6.
23. Van Veen NH, Lockwood DN, van Brakel WH, Ramirez J Jr, Richardus JH. Interventions for erythema nodosum leprosum. Cochrane Database Syst Rev 2009 July 8;(3)CD006949.
24. Namazi MR. Levamisole: A safe and economical weapon against pediculosis. Int J Dermatol 2001;40:292-4.
25. Papageorgiou P, Kesarvada HL, Alcid DV, Szep R, Kulkarni KN, Gocke DJ. Levamisole in chronic pyoderma. J Clin Lab Immunol 1982;8:121-7.
26. Djavari D, Hornstein OP. Recurrent chronic pyodermia with cellular immunodeficiency. Successful therapy by levamisole. Dermatologica 1980;161:116-23.
27. Castro Garzón M, Mubita M, Kachinka L. Levamisole treatment in HIV-infected Zambian children. Lancet 1992;340:1099-100.
28. Mansouri F, Janbakhsh A, Vaziri S, Sayad B, Asfarian M, Hosseinpor F, et al. Comparative study of levamisole-selenium supplementation effect on CD4 increase in HIV/AIDS patients. Caspian J Intern Med 2011;2:218-21.
29. Lozada-Nur F, Cram D, Gorsky M. Clinical response to levamisole in thirty-nine patients with erythema multiforme. An open prospective study. Oral Surg Oral Med Oral Pathol 1992;74:294-8.
30. Lozada F, Spiller L, Silverman S Jr. Clinical and immunologic responses to levamisole in 13 patients with erythema multiforme. Int J Immunopharmacol 1980;2:63-8.
31. Lozada F. Levamisole in the treatment of erythema multiforme: A double-blind trial in fourteen patients. Oral Surg Oral Med Oral Pathol 1982;53:28-31.
32. Sun A, Chia JS, Wang JT, Chiang CP. Levamisole can reduce the high serum tumour necrosis factor-alpha level to a normal level in patients with erosive oral lichen planus. Clin Exp Dermatol 2007;32:308-10.
33. Sun A, Chiang CP, Chiov PS, Wang JT, Liu BY, Wu YC. Immunomodulation by levamisole in patients with recurrent aphthous ulcers or oral lichen planus. J Oral Pathol Med 1994;23:172-7.
34. Lu SY, Chen WJ, Eng HL. Response to levamisole and low-dose prednisolone in 41 patients with chronic oral ulcers: A 3-year open clinical trial and follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86:438-45.
35. Won TH, Park SY, Kim BS, Seo PS, Park SD. Levamisole monotherapy for oral lichen planus. Ann Dermatol 2009;21:250-4.
36. Hamza M, Ayed K, Ben Ayed H. Treatment of Behcet's disease with levamisole. Arthritis Rheum 1982;25:714-5.
37. de Merieux P, Spiller LE, Paulus HE. Treatment of Behcet's syndrome with levamisole. Arthritis Rheum 1981;24:64-70.
38. De Croe J, Verlaegen H, De Cock W, Verbruggen F, A
randomized double-blind trial of levamisole in the therapy of recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol 1978:45:378-84.

39. Weckx LL, Hirata CH, Abreu MA, Fillizzola VC, Silva OM. Levamisole does not prevent lesions of recurrent aphthous stomatitis: A double-blind placebo-controlled clinical trial. Rev Assoc Med Bras 2009;55:132-8.

40. Ansarin H, Savabynasab S, Behzadi AH, Sadigh N, Hasanloo J. Doxycycline plus levamisole: Combination treatment for severe nodulocystic acne. J Drugs Dermatol 2008;7:737-40.

41. Rassai S, Mehr M, Yaghoobi R, Sina N, Mohabbipour A, Felly A. Superior efficacy of azithromycin and levamisole vs. azithromycin in the treatment of inflammatory acne vulgaris: An investigator blind randomized clinical trial on 169 patients. Int J Clin Pharmacol Ther 2013;51:490-4.

42. Haneke E. Levamisole treatment of acne fulminans (author's transl). Z Hautkr 1981;56:1160-6.

43. Westphal HJ, Schütz C, Kaben U, Mattheus A. Akne conglobata with immunodeficiency and its Levamisol treatment (author's transl). Dermatol Monatsschr 1981;167:410-7.

44. Agarwal S, Ramam M, Sharma VK, Khandpur S, Pal H, Pandey RM. A randomized placebo-controlled double-blind study of levamisole in the treatment of limited and slowly spreading vitiligo. Br J Dermatol 2005;153:163-6.

45. Pasricha JS, Khera V. Effect of prolonged treatment with levamisole on vitiligo with limited and slow-spreading disease. Int J Dermatol 1994;33:584-7.

46. Khondker L, Khan SI. Efficacy of levamisole for the treatment of slow spreading vitiligo. Mymensingh Med J 2014;13:276-6.

47. Roy R, Kalla G, Singhi MK. Levamisole in vitiligo of eyelids. Indian J Dermatol Venereol Leprol 1996;62:199-200.

48. Scherak O, Smolen J, Kolarz G, Kojer M, Menzel J. Clinical experience with levamisole treatment of patients with systemic lupus erythematosus (author's transl). Wien Klin Wochenschr 1979;91:758-62.

49. Rovenský J, Cebecauer L, Zitnan D, Lukác J, Ferencík M. Levamisole treatment of systemic lupus erythematosus. Arthritis Rheum 1982;25:470-1.

50. Liapon AO, Rutshtein LG, Roitburd MF, Fadeeva VI. Levamisole (decaris) in the complex treatment of different clinical forms of psoriasis. Vestn Dermatol Venerol 1984:4:61-6.

51. Lozada F, Silverman S, Cram D. Pemphigus vulgaris. A study of six cases treated with levamisole and prednisone. Oral Surg Oral Med Oral Pathol 1982;54:161-5.

52. Carl-Basset C, Renoux M, Pauley AM, Lorette G, Renoux G. Correlation between the immune reaction and clinical course in a bullous pemphigoid case treated with levamisole. LARC Med 1982;2:440-1.

53. Sehgal VN, Jain S, Kumar S, Bhattacharya SN, Singh N. Generalized lichen nitidus in a child's response to coticizine dihydrochloride/levamisol. Australas J Dermatol 1998;39:60.

54. Jautová J, Jarcusková D, Dubivská M, Ficová M. Immunostimulation therapy in patients with alopecia areata. Bratisl Lek Listy 1995:96:160-4.

55. Veien NK. Cutaneous sarcoidosis treated with levamisole. Dermatologica 1977;154:185-9.

56. Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: A phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991:9:729-35.

57. Symoens J, Veys E, Mielants M, Pinals R. Adverse reactions to levamisole. Cancer Treat Rep 1978;62:1721-30.

58. Kimmel DW, Schutt AJ. Multifocal leukoencephalopathy: Occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. Mayo Clin Proc 1993:68:363-5.

59. Kirby JD, Black M, McGibbon D. Levamisole-induced lichenoid eruptions. J R Soc Med 1980;73:208-11.

60. Fellner MJ, Ledesma GN. Leg ulcers secondary to drug reactions. Clin Dermatol 1990;8:144-9.

61. Powell J, Grech H, Holder J. A boy with cutaneous necrosis occurring during treatment with levamisole. Clin Exp Dermatol 2002;27:32-3.

62. Auffenberg C, Rosenthal LJ, Dressner N. Levamisole: A common cocaine adulterant with life-threatening side effects. Psychosomatics 2013:54:590-3.

63. Amer M, Tossoun Z, Soliman A, Selim AG, Salem A, al-Gendy AA. Verrucae treated by levamisole. Int J Dermatol 1991;30:738-40.

64. Bierman SM. Double-blind cross-over study of levamisole as immunophylaxis for recurrent herpes progenitalis. Cutis 1978;21:352-4.

65. Sharda N, Shashikanth MC, Kant P, Jain M. Levamisole and low-dose prednisolone in the treatment of recurrent aphthous stomatitis. J Oral Pathol Med 2014;43:309-16.

66. Picciani BL, Silva-Junior GO, Barbirato DS, Ramos RT, Cantisano MH. Regression of major recurrent aphthous ulcerations using a combination of intralesional corticosteroids and levamisole: A case report. Clinics (Sao Paulo) 2010;65:650-2.

67. Roy R, Kalla G, Singh MK. Levamisole in vitiligo of eyelids. Indian J Dermatol Venerol Leprol 1996;62:199-200.